Status:
COMPLETED
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese par...
Eligibility Criteria
Inclusion
- \- Body Mass Index (BMI) is \>= 19.0 to \<= 26.0 kg/m2 after rounding to the nearest tenth. BMI is calculated as weight in kg divided by the square of height measured in meters.
Exclusion
- \- Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.
Key Trial Info
Start Date :
June 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 26 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05268068
Start Date
June 27 2019
End Date
April 26 2020
Last Update
March 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Xuhui Central Hospital /ID# 212830
Shanghai, Shanghai Municipality, China, 200031